First Human Use of RUC‐4: A Nonactivating Second‐Generation Small‐Molecule Platelet Glycoprotein IIb/IIIa (Integrin αIIbβ3) Inhibitor Designed for Subcutaneous Point‐of‐Care Treatment of ST‐Segment–Elevation Myocardial Infarction

First Human Use of RUC‐4: A Nonactivating Second‐Generation Small‐Molecule Platelet Glycoprotein IIb/IIIa (Integrin αIIbβ3) Inhibitor Designed for Subcutaneous Point‐of‐Care Treatment of ST‐Segment–Elevation Myocardial Infarction

Background Despite reductions in door‐to‐balloon times for primary coronary intervention, mortality from ST‐segment–elevation myocardial infarction has plateaued. Early pre–primary coronary intervention treatment of ST‐segment–elevation myocardial infarction with glycoprotein IIb/IIIa inhibitors imp...

Full description

Bibliographic Details
Main Authors: Dean J. Kereiakes, Tim D. Henry, Anthony N. DeMaria, Ohad Bentur, Marilyn Carlson, Corinne Seng Yue, Linda H. Martin, Jeff Midkiff, Michele Mueller, Terah Meek, Deborah Garza, C. Michael Gibson, Barry S. Coller
Format: Article
Language:English
Published: Wiley 2020-09-01
Series:Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Subjects:
GPIIb/IIIa
myocardial infarction
platelet inhibitor
STEMI
Online Access:https://www.ahajournals.org/doi/10.1161/JAHA.120.016552

Internet

https://www.ahajournals.org/doi/10.1161/JAHA.120.016552

Similar Items